Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study

Breast Cancer Research

Volumn 13, Issue 2, 2011, Pages

  Oh, Sang W ^a   Park, Cheol Young ^b   Lee, Eun S ^c   Yoon, Yeong S ^d   Lee, Eon S ^d   Park, Sang S ^a,e   Kim, Yuil ^a   Sung, Nak J ^a   Yun, Young H ^f   Lee, Keun S ^f   Kang, Han S ^f   Kwon, Youngmee ^f   Ro, Jungsil ^f  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e TEXAS A AND M UNIVERSITY   (United States)

^f National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ESTROGEN RECEPTOR; INSULIN; LEPTIN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; AGED; BLOOD; BREAST TUMOR; CELL PROLIFERATION; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; PROGNOSIS; TUMOR RECURRENCE;

ADIPONECTIN; ADULT; AGED; BREAST NEOPLASMS; CELL PROLIFERATION; COHORT STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84860389875     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2856     Document Type: Article

References (35)

1. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer 1992, 52:511-516. 10.1002/ijc.2910520402, 1399128.
2. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998, 47:111-120. 10.1023/A:1005831013718, 9497099.
3. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009, 101:48-60. 2639294, 19116382.
4. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007, 86:s823-835.
5. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008, 114:63-70. 10.1080/13813450801954451, 18465360.
6. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, Krogh V. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr Metab Cardiovasc Dis 2009, 2819536, 19361966.
7. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, Chen HY, Hou MF, Yuan SS. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006, 237:109-114. 10.1016/j.canlet.2005.05.047, 16019138.
8. Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R, Jonsson H, Stattin P. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 2009, 113:567-576. 10.1007/s10549-008-9958-8, 18330696.
9. Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL, Sun Y, Wu Q, Chen L. Adipocytokines and breast cancer risk. Chin Med J (Engl) 2007, 120:1592-1596.
10. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CS. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007, 92:1041-1048. 10.1210/jc.2006-1858, 17192291.
11. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004, 89:1102-1107. 10.1210/jc.2003-031804, 15001594.
12. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003, 9:5699-5704.
13. Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, Hsu GC, Yu CP, Yu JC, Sun CA. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 2007, 14:669-677. 10.1677/ERC-06-0089, 17914097.
14. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, Hankinson SE. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007, 92:1510-1516. 10.1210/jc.2006-1975, 17213279.
15. Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007, 22:117-121. 10.3346/jkms.2007.22.1.117, 2693546, 17297263.
16. Kabat GC, Kim M, Chlebowski RT, Khandekar J, Ko MG, McTiernan A, Neuhouser ML, Parker DR, Shikany JM, Stefanick ML, Thomson CA, Rohan TE. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:2046-2053. 10.1158/1055-9965.EPI-09-0235, 19567502.
17. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005, 51:494-503. 10.1373/clinchem.2004.046227, 15637130.
18. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group.
19. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, Roh YK. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 2005, 28:1263-1269. 10.1007/BF02978210, 16350853.
20. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y, Pecquery R. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 2008, 20:971-977.
21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
22. Regitnig P, Reiner A, Dinges HP, Hofler G, Muller-Holzner E, Lax SF, Obrist P, Rudas M, Quehenberger F. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 2002, 441:328-334. 10.1007/s00428-002-0646-5, 12404057.
23. Wells CA, Sloane JP, Coleman D, Munt C, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Bussolati G, Connolly CE, Dervan P, Drijkoningen M, Ellis IO, Elston CW, Eusebi V, Faverly D, Heikkila P, Holland R, Jacquemier J, Lacerda M, Martinez-Penuela J, De Miguel C, Peterse JL, Rank F, Reiner A, Saksela E, Sigal-Zafrani B, Sylvan M, Borisch B, et al. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study. Virchows Arch 2004, 445:119-128.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
25. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982, 69:239-241.
26. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578. 10.1016/S0140-6736(08)60269-X, 18280327.
27. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003, 88:4823-4831. 10.1210/jc.2003-030214, 14557461.
28. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556. 10.1210/jc.2004-0395, 15181022.
29. Montecucco F, Mach F. Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. Diabetes Obes Metab 2009, 11:445-454. 10.1111/j.1463-1326.2008.00986.x, 19220391.
30. Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs 2006, 15:917-931. 10.1517/13543784.15.8.917, 16859394.
31. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94:1221-1225. 10.1038/sj.bjc.6603051, 2361397, 16570048.
32. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007, 14:189-206. 10.1677/ERC-06-0068, 17639037.
33. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006, 13:279-292. 10.1677/erc.1.00729, 16728564.
34. Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonanni B, Gulisano M, Magni P, Formelli F, Decensi A. Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 2008, 68:9512-9518. 10.1158/0008-5472.CAN-08-0553, 2599903, 19010927.
35. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162. 10.1074/jbc.M311113200, 14699128.